Context: Overactive bladder is treated mainly with behavioral and drug therapy, and symptoms of urinary frequency and incontinence are challenging to eliminate. There is thus a continuous unmet need for new drugs with a substitution effect mechanism. Objective: It not known whether vitamin D deficiency can lead to overactive bladder or urinary incontinence or whether vitamin D supplementation alleviates bladder symptoms. This comprehensive systematic review with meta-analysis was conducted to determine whether overactive bladder is associated with vitamin D deficiency. Data Sources: The PubMed and Cochrane Library databases were searched systematically up to July 3, 2022. Data Extraction: Initially, 706 articles were identified in the literature search, of which 13 were included in the systematic review: 4 randomized controlled trials, 3 cohort studies, 3 cross-sectional studies, and 3 case-control studies. Data Analysis: An increased risk of overactive bladder and urinary incontinence was observed with vitamin D deficiency (odds ratio [OR] = 4.46; 95%CI, 1.03–19.33; P = 0.046 and OR = 1.30; 95%CI, 1.01–1.66; P = 0.036, respectively). Vitamin D levels were relatively low in patients with overactive bladder or urinary incontinence (SMD = −0.33; 95%CI, −0.61 to −0.06, P = 0.019). On the basis of existing data, the risk of urinary incontinence was reduced by 66% after vitamin D supplementation (OR = 0.34; 95%CI, 0.18–0.66; P = 0.001). Egger test was conducted to assess publication bias, and the results were tested for robustness using a sensitivity analysis. Conclusions: Vitamin D deficiency increases the risk of overactive bladder and urinary incontinence, and vitamin D supplementation reduces the risk of urinary incontinence. The development of new strategies to prevent or alleviate bladder symptoms is crucial. Vitamin D supplementation may be gaining recognition as an effective strategy for prevention or alleviation of bladder symptoms such as overactive bladder and incontinence. Systematic Review Registration: PROSPERO registration no. CRD42022351443.
Hypospadias is among the most frequent congenital malformations of the male genitalia. The expression of V‐maf musculoaponeurotic fibrosarcoma oncogene homolog B ( MAFB ), a transcription factor within the androgen signaling pathway, is closely correlated with the etiology of this condition. From an epigenetic perspective, this study investigated the role of microRNA‐130a‐3p (miR‐130a‐3p) in regulating MAFB during hypospadias pathogenesis. Clinical foreskin samples from hypospadias children and the dioctyl phthalate (DEHP)‐induced mouse genital tubercle tissues were analyzed. The expression levels of miR‐130a‐3p and MAFB were detected by qRT‐PCR and western blot. In vitro, miR‐130a‐3p was modulated in HS68 cells; CCK‐8, scratch assay, western blot, flow cytometry, and dual‐luciferase assay were used to assess its effects and targeting of MAFB . Our study demonstrated that miR‐130a‐3p targeted and suppressed MAFB expression. This suppression inhibited cellular proliferation and migration and reduced Vimentin mRNA expression. Cell cycle distribution was disrupted, marked by Gap 1 phase increase and Synthesis phase reduction, and the cell apoptosis rate increased. Cyclin‐dependent kinase 2 (CDK2), Cyclin E1, and Proliferating Cell Nuclear Antigen (PCNA) were downregulated. miR‐130a‐3p targets and inhibits MAFB expression, disrupting the normal processes of cell proliferation, migration, cell apoptosis, and cell cycle progression, ultimately leading to the development of hypospadias.